Although the
SSRIs are likely to share pharmacodynamic interactions (for example development of the
serotonin syndrome with other serotonergic drugs) they do have differing effects on cytochrome P450, which leads to different metabolic actions. Fluvoxamine is a potent inhibitor of CYP1A2, whereas fluoxetine,
paroxetine, and possibly sertraline, have moderate inhibitory effects on CYP2D6.